Free Trial
NASDAQ:ALVO

Alvotech (ALVO) Stock Price, News & Analysis

Alvotech logo
$13.31 +0.09 (+0.68%)
As of 04:00 PM Eastern

About Alvotech Stock (NASDAQ:ALVO)

Key Stats

Today's Range
$13.16
$13.42
50-Day Range
$11.28
$13.52
52-Week Range
$9.15
$18.00
Volume
183,909 shs
Average Volume
146,589 shs
Market Capitalization
$4.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Alvotech Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
47th Percentile Overall Score

ALVO MarketRank™: 

Alvotech scored higher than 47% of companies evaluated by MarketBeat, and ranked 654th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alvotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alvotech has received no research coverage in the past 90 days.

  • Read more about Alvotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Alvotech are expected to grow in the coming year, from ($0.30) to $0.04 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alvotech is -7.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alvotech is -7.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.40% of the float of Alvotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Alvotech has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alvotech has recently increased by 244.24%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Alvotech does not currently pay a dividend.

  • Dividend Growth

    Alvotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.40% of the float of Alvotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Alvotech has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alvotech has recently increased by 244.24%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Alvotech has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Alvotech this week, compared to 3 articles on an average week.
Receive ALVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alvotech and its competitors with MarketBeat's FREE daily newsletter.

ALVO Stock News Headlines

Trump Insider: Day One will Shock Everyone
A rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market. But hurry... After January 20th, it could be too late.
Northland Securities Keeps Their Buy Rating on Alvotech (ALVO)
See More Headlines

ALVO Stock Analysis - Frequently Asked Questions

Alvotech's stock was trading at $13.23 at the start of the year. Since then, ALVO stock has increased by 0.6% and is now trading at $13.31.
View the best growth stocks for 2025 here
.

Alvotech (NASDAQ:ALVO) posted its quarterly earnings data on Thursday, August, 15th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.56. The firm had revenue of $198.75 million for the quarter.

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alvotech investors own include Micron Technology (MU), Arista Networks (ANET), United Microelectronics (UMC), Weatherford International (WFRD), NVIDIA (NVDA), PACCAR (PCAR) and Axcelis Technologies (ACLS).

Company Calendar

Last Earnings
8/15/2024
Today
1/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALVO
Fax
N/A
Employees
1,026
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$18.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+35.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-551,730,000.00
Net Margins
-123.47%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$391.87 million

Miscellaneous

Free Float
N/A
Market Cap
$4.01 billion
Optionable
Not Optionable
Beta
-0.19
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ALVO) was last updated on 1/14/2025 by MarketBeat.com Staff
From Our Partners